Cytosorbents Corp (OQ:CTSO)

Business Focus: Advanced Medical Equipment & Technology

May 02, 2024 07:00 am ET
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it...
Apr 26, 2024 07:00 am ET
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the...
Apr 17, 2024 07:00 am ET
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that...
Mar 14, 2024 04:39 pm ET
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported financial...
Mar 06, 2024 07:00 am ET
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at...
Feb 08, 2024 07:00 am ET
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the...
Jan 30, 2024 06:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Jan 26, 2024 12:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Jan 22, 2024 06:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
NEW YORK, Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. 
Jan 18, 2024 05:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Jan 17, 2024 07:15 am ET
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports on excellent...
Jan 14, 2024 10:45 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
NEW YORK, Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Jan 10, 2024 03:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Jan 08, 2024 09:00 pm ET
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO) on behalf of Cytosorbents stockholders. Our...
Jan 06, 2024 10:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
NEW YORK, Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Jan 02, 2024 03:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Dec 29, 2023 12:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
NEW YORK, Dec. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Dec 28, 2023 07:00 am ET
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces an update...
Dec 13, 2023 09:15 am ET
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces the closing...
Dec 05, 2023 08:31 am ET
Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, CYTO, NRSN, CTSO, and DBI.
Nov 09, 2023 04:15 pm ET
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited...
Oct 27, 2023 07:00 am ET
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2023 operating and financial results after the...
Oct 05, 2023 07:00 am ET
CytoSorbents to Present at the 8th Annual Dawson James Conference
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the...
Sep 27, 2023 07:00 am ET
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced the upcoming original...
Sep 21, 2023 09:35 am ET
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand...
Sep 19, 2023 07:00 am ET
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world,...
Sep 11, 2023 11:32 am ET
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, highlights the growing momentum of...
Sep 01, 2023 04:43 pm ET
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that Alexander D’Amico has...
Aug 31, 2023 07:00 am ET
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world,...
Aug 01, 2023 04:15 pm ET
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited...
Jul 26, 2023 07:00 am ET
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2023 operating and financial results after the...
Jul 19, 2023 07:00 am ET
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced the appointment...
Jul 11, 2023 07:00 am ET
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, and Humedics GmbH, a leader...
Jul 07, 2023 07:07 am ET
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has completed...
Jun 15, 2023 07:00 am ET
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has...
Jun 05, 2023 09:00 am ET
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its Virtual Annual Stockholders Meeting tomorrow,...
May 02, 2023 04:15 pm ET
CytoSorbents Reports First Quarter 2023 Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited...
Apr 26, 2023 07:00 am ET
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2023 operating and financial results after the...
Apr 20, 2023 07:00 am ET
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that its pivotal...
Apr 19, 2023 07:00 am ET
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that its...
Mar 29, 2023 08:30 am ET
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights the recently published study entitled, “CytoSorb hemoperfusion...
Mar 22, 2023 08:09 am ET
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced its scientific program for the 42nd International Symposium on...
Mar 14, 2023 07:00 am ET
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that it...
Mar 09, 2023 04:15 pm ET
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported financial...
Mar 07, 2023 07:00 am ET
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that hemoadsorption of antithrombotic drugs in cardiothoracic...
Feb 27, 2023 06:00 am ET
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference
PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Cowen 43rd Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Tuesday, March 7, 2023.  Company management will also meet in-person with investors in 1x1 meetings during the conference.  To schedule a meeting with management, please contact your Cowen representative.
Feb 24, 2023 06:00 am ET
CytoSorbents to Report Fiscal 2022 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9, 2023 at 4:30PM EST.
Jan 31, 2023 06:15 am ET
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product sales were within 5% of that achieved in 2021 and greater than 30% increased from pre-pandemic 2019 
Jan 23, 2023 06:00 am ET
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial
PRINCETON, N.J., Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial.
Jan 17, 2023 06:00 am ET
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs
Dr. Irina Kulinets, seasoned U.S. and international medical device regulatory expert, joins CytoSorbents' executive management team to lead FDA marketing approval of DrugSorb®-ATR and other global regulatory priorities
Dec 29, 2022 06:00 am ET
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement
Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initiatives
Dec 21, 2022 06:00 am ET
CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications
PRINCETON, N.J., Dec. 21, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received the recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial as planned without any modifications.  
Nov 14, 2022 06:00 am ET
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
PRINCETON, N.J., Nov. 14, 2022  /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial, achieving the first enrollment milestone and triggering a pre-specified Data and Safety Monitoring Board (DSMB) review.  This pivotal study intends to support both U.S. FDA and Health Cana
Nov 03, 2022 04:15 pm ET
CytoSorbents Reports Third Quarter 2022 Financial and Operational Results
CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month
Nov 02, 2022 08:33 am ET
Thinking about buying stock in Arcturus Therapeutics, Chegg, Match, Yum China, or Cytosorbents?
NEW YORK, Nov. 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARCT, CHGG, MTCH, YUMC, and CTSO.
Nov 02, 2022 07:10 am ET
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
90-day survival was 74% overall, with early intervention with ECMO and CytoSorb associated with improved survival, and shorter duration on ECMO, mechanical ventilation, and ICU stay compared to late intervention
Oct 31, 2022 07:00 am ET
National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma
Goal is to advance new combined blood purification technologies to treat Gram negative sepsis – a deadly global killer
Oct 27, 2022 07:00 am ET
CytoSorbents to Report Third Quarter 2022 Operating and Financial Results
PRINCETON, N.J., Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022. CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.
Oct 12, 2022 07:00 am ET
CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
PRINCETON, N.J., Oct. 12, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced the presentation of exciting new data on the use of CytoSorb® in various cardiac surgery indications at the 36th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting last week in Milan, Italy. 
Oct 07, 2022 07:05 am ET
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch
PRINCETON, N.J., Oct. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that its Chief Financial Officer, Kathleen P. Bloch, MBA, CPA, plans to retire on March 31, 2023 at age 68, following a distinguished decade-long career at the Company.  A search has been initiated for Ms. Bloch's replacement.  Meanwhile, following her retirement next year, Ms. Bloch will continue as a consultant
Oct 06, 2022 07:00 am ET
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma
PRINCETON, N.J., Oct. 6, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA™ filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma.  Without the need for blood typing, widespread availability of universal plasma could help save l
Oct 04, 2022 07:00 am ET
CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference
PRINCETON, N.J., Oct. 4, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12th, 2022. Company management will also meet with investors in 1x1 meetings throughout the conference.  To schedule a meeting with management, please contact your Dawson James representative.
Sep 27, 2022 08:20 am ET
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey
CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site
Sep 09, 2022 07:00 am ET
The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma
PRINCETON, N.J., Sept. 9, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the U.S. Army Medical Research Acquisition Activity, with funding from the Combat Casualty Care Research Program, awarded the Company a two-year grant (W81XWH-22-1-0235) valued at $1,977,024 to optimize development of the HemoDefend-BGA™ adsorber to a fully-finished, commercial device that will be evaluated
Sep 07, 2022 07:30 am ET
CytoSorbents to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRINCETON, N.J., Sept. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022. An on-demand webcast of the presentation will be accessible via the following Link. Company management will also meet with investors in 1x1 meetings throughout the conference.  
Aug 23, 2022 07:02 am ET
Turkish Ministry of Health Grants National Reimbursement to CytoSorb®
The cost of treatment with CytoSorb® will now be covered by the public sector in Turkey
Aug 17, 2022 07:02 am ET
Israeli Ministry of Health Approves National Coverage for CytoSorb®
PRINCETON, N.J., Aug. 17, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Israeli Ministry of Health (MoH) has approved national reimbursement for CytoSorb® in certain cardiac surgery indications that is expected to take effect in 2023.
Aug 02, 2022 04:17 pm ET
CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovationsCytoSorb will be featured on Fresenius Medical Care's critical care platforms for the removal of cytokines, bilirubin, and myoglobinFresenius Medical Care will be responsible for the specific worldwide marketing and combined promotion of CytoSorb with its critical care products utilizing multiple highly visible and prominent marketing channels and campaignsCytoSorbents' proprietary hemoadsorption CytoSorb thera
Aug 02, 2022 04:15 pm ET
CytoSorbents Reports Second Quarter 2022 Financial and Operational Results
PRINCETON, N.J., Aug. 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended June 30, 2022.
Jul 25, 2022 07:00 am ET
CytoSorbents to Report Second Quarter 2022 Operating and Financial Results
PRINCETON, N.J., July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2nd, 2022.  CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.
Jun 02, 2022 07:00 am ET
CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually
PRINCETON, N.J., June 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will host its Annual Meeting virtually on Tuesday, June 7, 2022, at 10:00 a.m. Eastern.  Stockholders of record as of April 14, 2022 will be able to virtually join and submit questions, and those that have not yet voted will be able to vote their shares electronically at the meeting.
Jun 01, 2022 07:00 am ET
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb®
May 19, 2022 07:00 am ET
CytoSorbents to Present at Two Upcoming Investor Conferences
MONMOUTH JUNCTION, N.J., May 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will present at two upcoming in–person investor conferences. 
May 03, 2022 04:15 pm ET
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook
Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million.  Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core product sales a year ago.  Product gross margins were 80%.
May 02, 2022 07:00 am ET
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
MONMOUTH JUNCTION, N.J., May 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group (Asklepios), one of the largest private hospital operators in Germany, following the majority acquisition of  RHÖN‑KLINIKUM AG in 2020.
Apr 29, 2022 07:00 am ET
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., April 29, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb™-ATR Antithrombotic Removal System for intraoperative removal of apixaban and ri
Apr 28, 2022 07:00 am ET
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress
MONMOUTH JUNCTION, N.J., April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in the 10th EuroELSO Congress (EuroELSO 2022) in London, UK being held May 4-6, 2022, one of the two major conferences for ECMO (extracorporeal membrane oxygenation) users worldwide.  CytoSorbents is highlighting the strategy of "enhanced lung rest" using CytoSorb with ECMO to help treat acute respiratory distress syndrome (A
Apr 19, 2022 07:00 am ET
CytoSorbents to Report First Quarter 2022 Operating and Financial Results
MONMOUTH JUNCTION, N.J., April 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2022 operating and financial results after the market close on May 3, 2022.  CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.
Apr 14, 2022 07:00 am ET
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via distributor partners within the region.  With a new direct commercialization presence, CytoSorbents expects to focus its resources and expertise to expa
Apr 07, 2022 07:00 am ET
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
MONMOUTH JUNCTION, N.J., April 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).
Apr 05, 2022 07:00 am ET
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors
MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents' Board of Directors as a new independent director, effective immediately, for a term expiring at the Company's 2022 Annual Meeting, scheduled for June 7, 2022, at which time Ms. Kim is expected to stand for re-election. 
Mar 17, 2022 07:00 am ET
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)
MONMOUTH JUNCTION, N.J., March 17, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in the 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM 2022) Congress in Brussels, Belgium being held March 22-25, 2022. CytoSorbents is a platinum sponsor of the Congress and will have a strong contingent of sales, marketing, and medical affairs personnel in attendance.
Mar 08, 2022 03:15 pm ET
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook
MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported audited financial and operating results for the quarter and year ended December 31, 2021 and provides its 2022 outlook.
Feb 08, 2022 06:00 am ET
CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022. CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.
Feb 03, 2022 06:00 am ET
CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences
MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.
Feb 01, 2022 06:00 am ET
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock
MONMOUTH JUNCTION, N.J., Feb. 1, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the PROCYSS (Prospective, Randomized, controlled trial with use Of CYtoSorb® to reverse refractory Septic Shock) trial in Germany by Prof. Dr. Stefan Kluge, Director, Department of Intensive Care Medicine at the University Hospital Hamburg Eppendorf and lead inve
Jan 18, 2022 06:00 am ET
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
MONMOUTH JUNCTION, N.J., Jan. 18, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, issues a stockholder letter from its Chief Executive Officer, Dr. Phillip Chan, and announces preliminary unaudited fourth quarter 2021 and full year 2021 results ahead of filing its Form 10-K. 
Dec 21, 2021 06:05 am ET
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
MONMOUTH JUNCTION, N.J., Dec. 21, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Professor Daniel Wendt, MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022. 
Dec 20, 2021 06:10 am ET
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
MONMOUTH JUNCTION, N.J., Dec. 20, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company's U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.
Nov 15, 2021 03:30 pm ET
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference
MONMOUTH JUNCTION, N.J., Nov. 15, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences.
Nov 04, 2021 04:15 pm ET
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results
MONMOUTH JUNCTION, N.J., Nov. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports full financial and operating results for the quarter ended September 30, 2021.
Oct 20, 2021 07:05 am ET
CytoSorbents Comments on REMOVE Study Presentation
MONMOUTH JUNCTION, N.J., Oct. 20, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb®1 blood purification, makes additional comments on the investigator-initiated REMOVE study following the formal presentation of trial results on Saturday, October 16th at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting in Barcelona, Spain.
Oct 14, 2021 07:05 am ET
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., Oct. 14, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic
Oct 12, 2021 04:38 pm ET
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During
MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the full approval of its Investigational Device Exemption (IDE) application by the FDA to conduct the pivotal STAR–D (Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants [DOAC]) double-blind, randomized, controlled trial in the United States to support FDA marketing approval.  This is being performed und
Oct 12, 2021 04:35 pm ET
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance
MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces preliminary third quarter financial results and revised second half and full year 2021 product revenue guidance, primarily reflecting pandemic-driven adverse market conditions in Germany.
Oct 07, 2021 03:11 pm ET
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference
MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) annual meeting taking place in Barcelona, Spain from October 13-16, 2021, where more extensive data are expected to be made available.  A summary of the abstract
Sep 14, 2021 09:25 am ET
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
MONMOUTH JUNCTION, N.J., Sept. 14, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming live webinar to provide a global perspective on CytoSorb® blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT / 5:00 p.m. CET.  The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COVID-19 patients worldwide, including the r
Sep 13, 2021 07:08 am ET
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies
MONMOUTH JUNCTION, N.J., Sept. 13, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces key sepsis-related events, sponsorships and studies in conjunction with World Sepsis Day today and Sepsis Awareness Month (September).
Sep 10, 2021 07:08 am ET
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urg
MONMOUTH JUNCTION, N.J., Sept. 10, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, "Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D)," in the United States to support FDA marketing approval.  This is being performed under the previously announced FDA Brea
Sep 08, 2021 04:15 pm ET
CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
MONMOUTH JUNCTION, N.J., Sept. 8, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces a special Company webinar highlighting  the topline results of CytoSorbents' U.S. CTC Multicenter Registry that demonstrate high survival using CytoSorb® in Critically Ill COVID-19 patients on ECMO, on Monday, September 13, 2021, at 5:00 p.m. EDT.
Sep 01, 2021 07:08 am ET
Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
MONMOUTH JUNCTION, N.J., Sept. 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced that topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry were presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) in Brussels, Belgium yesterday.  The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respiratory distress syndrome (ARDS) on life suppo
Aug 30, 2021 07:08 am ET
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress
MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the commercial launch of Aferetica's PerLife™ ex vivo organ perfusion system for kidney and liver transplant and CytoSorbents' PerSorb™ adsorber, based on the CytoSorbents ECOS-300CY™ sorbent technology to remove inflammatory mediators during ex vivo organ perfusion, at the European Society of Organ Transplantation (ESOT) Congress in Milan, Italy from August 29 – September 1,
Aug 12, 2021 09:31 am ET
Thinking about buying stock in Xeris Pharmaceuticals, Hims & Hers Health, Dynavax Technologies, CTI BioPharma, or Cytosorbents?
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XERS, HIMS, DVAX, CTIC, and CTSO.
Aug 12, 2021 07:03 am ET
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardi
MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA). This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary byp
Aug 03, 2021 04:15 pm ET
CytoSorbents Reports Second Quarter 2021 Financial and Operational Results
MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports financial and operating results for the quarter and six months ending June 30, 2021.
Jul 30, 2021 07:08 am ET
CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE
MONMOUTH JUNCTION, N.J., July 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the successful completion of its MISSION 100,000 international fundraising campaign to fight the spread of COVID-19, raising $100,000 to benefit the global, not-for-profit humanitarian organization, CARE. The funds raised for CARE's Crisis Response Campaign enable the organization to provide various vaccination, educati
Jul 19, 2021 07:08 am ET
CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
MONMOUTH JUNCTION, N.J., July 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, will report second quarter 2021 operating and financial results after the market close on August 3, 2021.
Jul 06, 2021 07:05 am ET
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) double-blind, randomized, controlled trial (RCT) in the United States to support FDA regulatory clearance.  This study is being performed under the previously announced FDA Breakthrough Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit during urgent and emergent cardiothoracic surgery with CytoSor
Feb 24, 2021 06:08 am ET
CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
MONMOUTH JUNCTION, N.J., Feb. 24, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Cowen 41st Annual Health Care Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present a brief overview of the Company's progress and outlook followed by a fireside chat with Joshua Jennings, MD, Managing Director, Senior Research Analyst, Equity Research at C
Feb 18, 2021 06:08 am ET
CytoSorbents 2021: Leadership and Growth in the "New Normal"
MONMOUTH JUNCTION, N.J., Feb. 18, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan.  Additional detail will be forthcoming in the Company's Q4 and Full Year 2020 earnings press release and Form 10-K, expected March 9, 2021.
Feb 16, 2021 06:08 am ET
CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
MONMOUTH JUNCTION, N.J., Feb. 16, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will discuss the Company's progress and outlook with Danielle Antalffy, Managing Director, Medical Devices, Equity Research at SVB Leerink in a fireside chat format.  Com
Feb 04, 2021 06:08 am ET
National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac Surgery
MONMOUTH JUNCTION, N.J., Feb. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, highlights the recent release from the United Kingdom's internationally renowned National Institute for Health and Care Excellence (NICE) of a Medtech Innovation Briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery.
Jan 21, 2021 06:08 am ET
CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs
MONMOUTH JUNCTION, N.J., Jan. 21, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of David D. Cox, Ph.D., M.B.A., as Vice President – Global Regulatory Affairs.
Jan 19, 2021 06:08 am ET
CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care
MONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that the Korean Ministry of Food and Drug Safety (KMFDS) has approved CytoSorb for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and
Jan 12, 2021 06:00 am ET
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwide
Jan 12, 2021 06:00 am ET
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwide
Jan 12, 2021 05:58 am ET
CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue
MONMOUTH JUNCTION, N.J., Jan. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.
Jan 11, 2021 05:00 am ET
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
MONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of James Komsa as Vice President - U.S. Sales and Marketing.
Jan 04, 2021 05:30 am ET
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
MONMOUTH JUNCTION, N.J., Jan. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that Health Canada has granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients under Interim Order (IO) ID# 316575.  CytoSorbents will collaborate with ebbtides medical, a specialty distributor of medical products throughout Canad
Dec 17, 2020 06:08 am ET
CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing
MONMOUTH JUNCTION, N.J., Dec. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the promotion of Dr. Christian Steiner to Executive Vice President - Sales and Marketing of CytoSorbents Corporation, effective immediately.  Dr. Steiner will continue as Co-Managing Director of CytoSorbents Europe GmbH, and its subsidiaries.
Dec 10, 2020 06:00 am ET
CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank
MONMOUTH JUNCTION, N.J., Dec. 10, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces it has closed on the Third Amendment (the "Amendment") of its Amended Loan and Security Agreement with Bridge Bank.  Under the terms of the Amendment, which closed on December 4, 2020 (the "Closing Date"), the Company repaid the outstanding principal balance of its existing $15 million term loans and
Dec 09, 2020 05:45 am ET
Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study
MONMOUTH JUNCTION, N.J., Dec. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, highlights the publication of a 'genetic' matched analysis evaluating the early initiation of CytoSorb in critically ill patients with septic shock.
Dec 02, 2020 06:08 am ET
CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE
MONMOUTH JUNCTION, N.J., Dec. 2, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader that is commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the launch of its international fundraising campaign to raise $100,000 to benefit the global, not-for-profit humanitarian organization, CARE USA.  The international campaign, which begins today and runs through January 31, 2021, commemorates a major company milestone of having cumulatively shi
Nov 25, 2020 06:08 am ET
CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients
MONMOUTH JUNCTION, N.J., Nov. 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the publication of the largest case series using CytoSorb in critically ill COVID-19 patients to date.
Nov 23, 2020 06:00 am ET
CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference
MONMOUTH JUNCTION, N.J., Nov. 23, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, is pleased to announce its participation at the Piper Sandler 32nd Annual Healthcare Conference.  Presentations will be available to registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020.  The Company will meet with investors in 1x1 meetings throughout December 1-3, 20
Nov 12, 2020 01:00 am ET
CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference
MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 and meet with investors in 1x1 meetings throughout the day.  For European investors, please contact your Jefferies representative to assist with scheduling.
Nov 04, 2020 03:15 pm ET
CytoSorbents Reports Record Third Quarter 2020 Financial Results
MONMOUTH JUNCTION, N.J., Nov. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its full financial and operational results for the quarter ending September 30, 2020.
Oct 21, 2020 07:08 am ET
CytoSorbents to Report Q3 2020 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Oct. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2020 financial results after the market close on Wednesday, November 4, 2020.  CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2020 followed by a question and answer session.
Oct 14, 2020 07:00 am ET
CytoSorbents and Aferetica Announce European Union Approval of the PerLife™ System and ECOS-300CY™ PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant
NEW JERSEY and BOLOGNA, Italy, Oct. 14, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO; USA) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the European Union approval of Aferetica's PerLife™ ex vivo organ perfusion system and CytoSorbents' ECOS-300CY™ sorbent cartridge for the removal of inflammatory mediators during ex vivo organ perfusion.  The integrated system was developed in concert to improve the preservation and quality of solid organs, like the kidneys and liver, following harvest and prior to transplant into a
Aug 31, 2020 05:00 pm ET
LD Micro 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 04, 2020 04:15 pm ET
CytoSorbents Reports Record Second Quarter 2020 Financial Results
MONMOUTH JUNCTION, N.J., Aug. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its full financial and operational results for the quarter ending June 30, 2020.
Aug 03, 2020 07:00 am ET
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date
MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that it has reached a major milestone in the history of the company with the cumulative delivery of more than 100,000 CytoSorb cartridges to date to hospitals around the world, including those here in the United States.  CytoSorb is distributed in a total of 65 countries globally.
Jul 31, 2020 07:08 am ET
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), has awarded the Company a three-year contract valued at up to $4,421,487 as part of a Peer Reviewed Medical Research Program Technology/Therapeutic Development Award to complete preclinical development of the HemoDefend™-BGA plasma and whole
Jul 28, 2020 07:08 am ET
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Data Monitoring Committee (DMC) of the REFRESH 2-AKI trial has completed a comprehensive favorable review of safety data from the study with a positive recommendation to resume the trial.
Jul 28, 2020 06:00 am ET
CytoSorbents to Report Q2 2020 Operating and Financial Results
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO),  CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2020 financial results after the market close on Tuesday, August 4, 2020. 
Jul 22, 2020 07:22 am ET
CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock
MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the pricing of its previously announced underwritten public offering of 5,263,158 shares of its common stock at a public offering price of $9.50 per share, resulting in gross proceeds of approximately $50.0 million before deducting underwriting discounts and c
Jul 20, 2020 04:51 pm ET
CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update
MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provides preliminary Q2 2020 financial highlights and a brief corporate update.
Jul 20, 2020 04:26 pm ET
CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock
MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has commenced a $40 million underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connec
Jul 08, 2020 07:00 am ET
/C O R R E C T I O N -- CytoSorbents Corporation/
In the news release, CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding, issued 29-Jun-2020 by CytoSorbents Corporation over PR Newswire, we are advised by the company that the conference call details and webcast information has changed. To reflect this, the third hyperlink in the first paragraph has been updated. Additionally, the "Key Opinion Leader Call Details" section after the third paragraph has been updated. The complete, corrected release follows:
Jun 29, 2020 07:08 am ET
CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding
MONMOUTH JUNCTION, N.J., June 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that CytoSorbents will host a Key Opinion Leader call on the Use of CytoSorb to Remove Antithrombotic Medications in Patients at Risk of Bleeding, on Monday, July 13, 2020 at 11:00 AM EDT, featuring presentations by key experts:
Jun 24, 2020 07:30 am ET
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the commercial launch and immediate availability of CytoSorb in nine Latin American countries including Colombia, Argentina, Perú, Guatemala, Ecuador, Bolivia, the Dominican Republic, El Salvador, and Costa Rica.  CytoSorb has been available in Panamá and Chile for many years, has recently received marketing ap
Jun 09, 2020 07:08 am ET
CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials
MONMOUTH JUNCTION, N.J., June 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract, valued at up to $2,897,172 over 2 years, to advance its HemoDefend-BGA plasma and whole blood adsorber to human clinical trials.  The program, entitled "Development of a Highly Efficient Adsorber to Remove Anti-A and Anti-B Antibodies from Blood and Plasma for Transfusion," is being funded by the U.S. Army M
May 27, 2020 12:00 pm ET
CytoSorbents Announces Virtual Annual Meeting
MONMOUTH JUNCTION, N.J., May 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, will host its Virtual Annual Meeting on Tuesday, June 2, 2020 at 10:00 AM EDT.  Stockholders of record will be able to virtually join and submit questions, and those that have not yet voted will be able to vote their shares electronically at the meeting.
May 12, 2020 07:08 am ET
CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., May 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb® is now approved and immediately available in the European Union for the removal of rivaroxaban (Xarelto®- Bayer, Jansenn/Johnson & Johnson), a widely-used Factor Xa inhibitor and novel oral anticoagulant  (NOAC), during cardiothoracic surgery requiring cardiopulmonary bypass (CPB).  With this announcement, and the E.U. approval earlier this year to remove the P2Y12 anti-platelet inhibitor, ticagrelo
May 05, 2020 04:15 pm ET
CytoSorbents Reports First Quarter 2020 Financial and Operational Results
MONMOUTH JUNCTION, N.J., May 5, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports record financial and operational results for the quarter ending March 31, 2020.
May 04, 2020 07:08 am ET
CytoSorbents Promotes Vincent J. Capponi to President
MONMOUTH JUNCTION, N.J., May 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, and its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, announced the promotion of Chief Operating Officer Vincent J. Capponi to President and COO, effective immediately.
Apr 29, 2020 07:00 am ET
CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program
MONMOUTH JUNCTION, N.J., April 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has received $1,092,698, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA).
Apr 28, 2020 08:00 am ET
CytoSorbents to Report Q1 2020 Operating and Financial Results
MONMOUTH JUNCTION, N.J., April 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2020 financial results after the market close on Tuesday, May 5, 2020. 
Apr 27, 2020 07:08 am ET
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
MONMOUTH JUNCTION, N.J., April 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the appointment of Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI as Chief Medical Officer, to begin employment on May 1, 2020.
Apr 20, 2020 06:58 am ET
Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., April 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a  critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation to CytoSorb for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.  The Breakthrough Devices Program provides for more effective tre
Apr 15, 2020 07:00 am ET
New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO
MONMOUTH JUNCTION, N.J., April 15, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a  critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a recently published study entitled, "Combined Use of CytoSorb and ECMO in Patients with Severe Pneumogenic Sepsis" in the medical journal, The Thoracic and Cardiovascular Surgeon. 
Apr 13, 2020 07:43 am ET
U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection
MONMOUTH JUNCTION, N.J., April 13, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a  critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the United States Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) of CytoSorb® for use in patients with COVID-19 infection. 
Apr 03, 2020 12:06 pm ET
CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today
MONMOUTH JUNCTION, N.J., April 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD will participate in a conference call, in fireside chat format, with Dr. Joshua Jennings, MD, Managing Director and Senior Research Analyst of Equity Research at Cowen and Company, LLC today to discuss the COVID-19 pandemic
Mar 31, 2020 07:08 am ET
CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
MONMOUTH JUNCTION, N.J., March 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CytoSorb cytokine adsorber has been approved to be marketed and sold in Mexico by the country's health authority, COFEPRIS. COFEPRIS, or the Federal Committee for Protection from Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios) is responsible
Mar 25, 2020 09:31 am ET
Thinking about buying stock in Cytosorbents, Darden Restaurants, Ford, KB Home, or MGM Resorts?
NEW YORK, March 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTSO, DRI, F, KBH, and MGM.
Mar 25, 2020 07:19 am ET
CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
MONMOUTH JUNCTION, N.J., March 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provided an update from its Chief Executive Officer, Dr. Phillip Chan, MD, PhD.
Nov 06, 2019 04:15 pm ET
Dr. Eric Mortensen to Leave CytoSorbents At Year End
MONMOUTH JUNCTION, N.J., Nov. 6, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Dr. Eric Mortensen, Chief Medical Officer of CytoSorbents, will leave the company at the end of the year, upon the completion of his current employment contract.                                          
Nov 05, 2019 03:15 pm ET
CytoSorbents Reports Third Quarter 2019 Financial Results
MONMOUTH JUNCTION, N.J., Nov. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending September 30, 2019.
Nov 04, 2019 06:05 am ET
CytoSorbents Announces Additions to its International Clinical Team
MONMOUTH JUNCTION, N.J., Nov. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces additions to its international clinical team.
Nov 01, 2019 07:15 am ET
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
MONMOUTH JUNCTION, N.J., Nov. 1, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies to treat life-threatening conditions, announced the first patient enrollment in the company-sponsored Ticagrelor CytoSorb® Hemoadsorption (TISORB) study in the United Kingdom (U.K.).  The Company also announced establishment of a new U.K. operating subsidiary, CytoSorbents UK Limited, that enables it, among other things, to be eligible for certain research tax credits that are expected to subsidize the trial by up to a third of the cost, subject to certain r
Oct 30, 2019 07:30 am ET
CytoSorbents to Report Q3 2019 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Oct. 30, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2019 financial results after the market close on Tuesday, November 5, 2019. 
Oct 22, 2019 08:12 am ET
CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia
MONMOUTH JUNCTION, N.J., Oct. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Air Force Materiel Command has awarded the Company a two-year contract valued at up to $2,959,747 as part of the Rapid Innovation Fund (RIF) to advance its program, entitled "K+ontrol Renal Support System for Reduction of Hyperkalemia," towards a U.S. clinical trial designed to support U.S. FDA regulatory approval.
Oct 10, 2019 07:00 am ET
CytoSorbents to Present at The MicroCap Rodeo Investor Conference
MONMOUTH JUNCTION, N.J., Oct. 10, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that company management will present an overview of the company at The MicroCap Rodeo Investor Conference on Tuesday, October 15, 2019 in Austin, TX and meet with investors in 1x1 meetings throughout the day.
Oct 04, 2019 07:08 am ET
CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery
MONMOUTH JUNCTION, N.J., Oct. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in hemoadsorption therapies to treat life-threatening conditions, announced that Dr. Eric Mortensen, MD, PhD, Chief Medical Officer of CytoSorbents, will present data from a new study on the cost effectiveness of CytoSorb when used intraoperatively to remove ticagrelor in patients undergoing emergency open heart surgery.  The presentation will occur at the 33rd Annual Meeting of the European Association for Cardio-Thoracic Surgery  (EACTS) in Lisbon, Portugal on Saturday, October 5, 2019. 
Oct 02, 2019 08:24 am ET
CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., Oct. 2, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader using its CytoSorb® blood purification technology to treat life-threatening medical and surgical conditions around the world, announces positive surgical outcomes in a recent publication entitled, "CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding," in the journal Annals of Thoracic Surgery, ahead of the European Association of Cardio-thoracic Surgery Annual Meeting in Lisbon, Portugal, October 3-5, 2019.
Sep 25, 2019 06:58 am ET
CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock
MONMOUTH JUNCTION, N.J., Sept. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a new publication entitled, "Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study," in the journal Critical Care.
Sep 16, 2019 07:00 am ET
First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence
MONMOUTH JUNCTION, N.J., Sept. 16, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Hannover Medical School in Germany will begin the first clinical study called CYTORELEASE, evaluating the use of CytoSorb in treating CRS and inflammation of the brain called CAR-related Encephalopathy Syndrome (CRES), following CAR-T cell immunotherapy. 
Sep 13, 2019 07:08 am ET
World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis
MONMOUTH JUNCTION, N.J., Sept. 13, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to help patients survive sepsis and other life-threatening inflammatory conditions, commemorates World Sepsis Day 2019 through the proud sponsorship of multiple organizations that are promoting sepsis awareness and education, early detection, prompt treatment, and basic and clinical sepsis research.
Sep 09, 2019 07:00 am ET
CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference
MONMOUTH JUNCTION, N.J., Sept. 9, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Tuesday, September 10, 2019 in New York, NY. Both Dr. Chan and Chief Financial Officer, Kathleen Bloch will me
Aug 28, 2019 09:51 am ET
CytoSorbents Highlights Recent Published Studies on CytoSorb
MONMOUTH JUNCTION, N.J., Aug. 28, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights recent published studies on CytoSorb in multiple applications.
Aug 15, 2019 01:54 pm ET
CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022
MONMOUTH JUNCTION, N.J., Aug. 15, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb has received renewal of its European Union CE Mark through May 2024 and ISO 13485:2016 Full Quality Assurance System certification of its manufacturing facility through September 2022.
Aug 13, 2019 07:08 am ET
CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica
MONMOUTH JUNCTION, N.J., Aug. 13, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, expands CytoSorb distribution to Brazil, Colombia and Costa Rica, with Contatti Medical, Service & Medical Colombia, and Nutricare Costa Rica, respectively.
Aug 06, 2019 04:15 pm ET
CytoSorbents Reports Record Second Quarter 2019 Financial Results
MONMOUTH JUNCTION, N.J., Aug. 6, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending June 30, 2019.
Aug 05, 2019 05:00 pm ET
CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan
MONMOUTH JUNCTION, N.J., Aug. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces it has received an additional $5 million in cash through an amended loan agreement with Bridge Bank's Life Sciences Group.
Jul 30, 2019 07:00 am ET
CytoSorbents to Report Q2 2019 Operating and Financial Results
MONMOUTH JUNCTION, N.J., July 30, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2019 financial results after the market close on Tuesday, August 6, 2019. 
May 20, 2019 07:00 am ET
CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference
MONMOUTH JUNCTION, N.J., May 20, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the B. Riley FBR 20th Annual Institutional Investor Conference on Wednesday, May 22, 2019 at 8:00AM PDT in Beverly Hills, CA.
May 07, 2019 04:15 pm ET
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
MONMOUTH JUNCTION, N.J., May 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2019.
May 01, 2019 07:00 am ET
CytoSorbents to Report Q1 2019 Operating and Financial Results
MONMOUTH JUNCTION, N.J., May 1, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2019 financial results after the market close on Tuesday, May 7, 2019.
Apr 24, 2019 07:08 am ET
CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences
MONMOUTH JUNCTION, N.J. and BERLIN, April 24, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, shares highlights from the recent 6th International CytoSorb Users' Meeting and the Satellite Symposium at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium, and the 8th Annual EuroELSO 2019 Conference held recently in Barcelona, Spain.
Apr 08, 2019 08:15 am ET
Recent Analysis Shows Acuity Brands, VICI Properties, Interface, Cytosorbents, Digimarc, and USA Technologies Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Acuity Brands Inc (NYSE:AYI), VICI Properties Inc. (NYSE:VICI),...
Apr 08, 2019 05:30 am ET
CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London
MONMOUTH JUNCTION, N.J., April 8, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company to European investors today, Monday, April 8, 2019, at the H.C. Wainwright Global Life Sciences Conference 2019 in London, England.  Dr. Chan will be joined by Chief Financial Officer, Kathleen Bloch for one-on
Mar 25, 2019 07:10 am ET
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
MONMOUTH JUNCTION, N.J., March 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that the Medical Device Division of the State of Israel Ministry of Health medical device regulation unit (AMAR), has granted registration of CytoSorb in Israel, clearing the way to begin selling the device in the country.
Mar 07, 2019 03:15 pm ET
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
MONMOUTH JUNCTION, N.J., March 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record total revenue, CytoSorb® sales, and product gross margins in 2018.
Mar 06, 2019 06:00 am ET
CytoSorbents to Present at the Cowen 39th Annual Health Care Conference
MONMOUTH JUNCTION, N.J., March 6, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 at 2:50PM EDT in Boston.  Dr. Chan and Chief Financial Officer, Ms. Kathleen Bloch will additionally meet with investors in sc
Mar 05, 2019 06:10 am ET
CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands
MONMOUTH JUNCTION, N.J., March 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has expanded direct sales of CytoSorb for all applications to Poland and the Netherlands, and for critical care applications in Sweden, Denmark, and Norway.  As part of this effort, the company established CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH. 
Feb 28, 2019 06:00 am ET
CytoSorbents to Report Fiscal 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Feb. 28, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2018 financial results on Thursday, March 7, 2019 at 4:45PM EST. 
Feb 25, 2019 06:08 am ET
CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference
MONMOUTH JUNCTION, N.J., Feb. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will participate in a fireside chat to discuss the company at the 8th Annual SVB Leerink Global Healthcare Conference this Wednesday, February 27, 2019 at 10:00AM EST in New York City.
Feb 05, 2019 06:00 am ET
CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
MONMOUTH JUNCTION, N.J., Feb. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the 21st Annual BIO CEO & Investor Conference next week in New York City.
Feb 04, 2019 05:58 am ET
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
MONMOUTH JUNCTION, N.J., Feb. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Data Safety Monitoring Board (DSMB) of the German government-funded REMOVE Endocarditis trial recommended continuation of the study following an interim analysis on the first 50 patients of the study.
Jan 23, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Shell Midstream Partners, Interface, National Western Life Group, TPG Specialty Lending, Francesca's, and Cytosorbents — What Drives Growth in Today's Compe
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Shell Midstream Partners, L.P. (NYSE:SHLX), Interface, Inc....
Jan 22, 2019 06:08 am ET
CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care
MONMOUTH JUNCTION, N.J., Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced today that it has expanded its partnership with Fresenius Medical Care to Korea and Mexico.
Jan 07, 2019 08:20 am ET
CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results
MONMOUTH JUNCTION, N.J., Jan. 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, and pre-announces preliminary unaudited fourth quarter 2018 and full-year 2018 results ahead of filing its Form 10-K.
Jan 04, 2019 06:00 am ET
CytoSorbents To Highlight Progress at Biotech Showcase 2019
MONMOUTH JUNCTION, N.J., Jan. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,  announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will provide a corporate update and highlight the company's progress at the Biotech Showcase 2019  conference on Monday, January 7, 2019 at 10:30 AM PST in San Francisco, California.  Dr. Chan will be joined by Ms. Kathleen Bloch, Chief Financial Officer,
Dec 21, 2018 07:45 am ET
CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
MONMOUTH JUNCTION, N.J., Dec. 21, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will receive $619,546, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA). 
Nov 26, 2018 06:00 am ET
CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference
MONMOUTH JUNCTION, N.J., Nov. 26, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the 30th Annual Piper Jaffray Healthcare Conference in New York City on November 29, 2018.  Dr. Chan and Chief Financial Officer, Ms. Kathleen Bloch will additionally meet with investors in schedul
Nov 19, 2018 06:08 am ET
CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500™
MONMOUTH JUNCTION, N.J., Nov. 19, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company was once again recognized as one of the fastest growing companies in North America on Deloitte's 2018 Technology Fast 500™, a ranking of the top 500 technology, media, telecommunications, healthcare and life sciences, and energy tech companies in terms of revenue growth on the contin
Nov 12, 2018 06:08 am ET
CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week
MONMOUTH JUNCTION, N.J., Nov. 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, and Chief Financial Officer, Ms. Kathleen Bloch, MBA, will separately present an overview of the company at multiple healthcare conferences this week.
Nov 09, 2018 08:00 am ET
Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Paramount Group, Inc. (NYSE:PGRE), Envestnet, Inc (NYSE:ENV), Assurant,...
Nov 06, 2018 03:15 pm ET
CytoSorbents Reports Third Quarter 2018 Financial Results
MONMOUTH JUNCTION, N.J., Nov. 6, 2018 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending September 30, 2018.
Oct 31, 2018 07:00 am ET
CytoSorbents to Report Q3 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Oct. 31, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2018 financial results after the market close on Tuesday, November 6, 2018. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.